

Variant: *NM\_000277.2(PAH):c.533A>G (p.Glu178Gly)*

Version: 1.1

CA273110 [↗](#)

92746 (ClinVar) [↗](#)

**Gene:** PAH (HGNC:5053)

**Condition:** phenylketonuria (MONDO:0009861)

**Inheritance Mode:** Autosomal recessive inheritance

**UUID:** 9cbb36d6-2daf-4507-b947-3a692ec4d9e7

**Approved on:** 2025-04-18

**Published on:** 2025-04-18

### *HGVS expressions*

**NM\_000277.2:c.533A>G**

NM\_000277.2(PAH):c.533A>G (p.Glu178Gly)

NC\_000012.12:g.102855309T>C

CM000674.2:g.102855309T>C

NC\_000012.11:g.103249087T>C

CM000674.1:g.103249087T>C

NC\_000012.10:g.101773217T>C

NG\_008690.1:g.67294A>G

NG\_008690.2:g.108102A>G

ENST00000553106.6:c.533A>G

ENST00000307000.7:c.518A>G

ENST00000549111.5:n.629A>G

ENST00000551988.5:n.554A>G

ENST00000553106.5:c.533A>G

NM\_000277.1:c.533A>G

NM\_001354304.1:c.533A>G

NM\_000277.3:c.533A>G

NM\_001354304.2:c.533A>G

**Pathogenic**

Met criteria codes **5**

PM3\_Strong PS3\_Supporting

PM2\_Supporting PP3\_Moderate

PP4\_Moderate

Evidence Links **0**

Expert Panel

Phenylketonuria VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** *ClinGen Phenylketonuria Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PAH Version 2.0.0*

[↗](#) **Criteria Specification Approval History**











[↗](#) **Criteria Specifications for this VCEP**

Evidence submitted by expert panel

**Phenylketonuria VCEP**

The c.533A>G variant in PAH is a missense variant predicted to cause substitution of glutamine by glycine at amino acid 178 (p.Glu178Gly). At least 5 patients with this variant displayed serum Phe levels > 6.5-10 mg/dl which is highly specific for PAH deficiency; BH4 deficiency was excluded (PP4\_moderate, PMID: 18299955, PMID:9634518). Of those individuals, 4 probands were compound heterozygous for the variant and a pathogenic variant and 1 proband was compound heterozygous with a likely pathogenic variant (phase unknown, 2.25 points). The population allele frequency in gnomAD v4.1 is 0.00003965 which is lower than the ClinGen PAH VCEP threshold (<0.0002) for PM2\_Supporting, meeting this criterion (PM2\_Supporting). The results from in silico predictors [REVEL=0.841], predict a damaging effect on PAH function (PP3\_moderate). Enzyme activity assay showed 39% residual phenylalanine hydroxylase activity indicating that this variant impacts protein function (PMID:17935162)(PS3\_supporting). In summary, this variant meets criteria to be classified as pathogenic for PAH deficiency in an autosomal recessive manner based on the ACMG/AMP criteria applied, as specified by the ClinGen PAH Expert Panel: PM2\_supporting, PP3\_moderate, PS3\_supporting, PP4\_Moderate, PM3\_Strong (version 2.0, 11/16/2024).

#### Met criteria codes

<b>PM3_Strong</b>			Detected with 3 pathogenic variants in 4 probands (0.5 points x 4 = 2.0 points) and 1 likely pathogenic variant (P281L) in 1 proband (0.25 points); phase unknown. 2.25 points
<b>PS3_Supporting</b>			39% residual phenylalanine hydroxylase activity
<b>PM2_Supporting</b>			Total AF 0.00003965 in gnomAD v4.1
<b>PP3_Moderate</b>			REVEL=0.841
<b>PP4_Moderate</b>			Detected in at least 5 patients with serum Phe levels > 6.5-10 mg/dl. BH4 deficiency excluded. PMID: 18299955, PMID: 9634518

#### Curation History

▼

▼

Showing 1 to 2 of 2 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.